<DOC>
	<DOCNO>NCT00842595</DOCNO>
	<brief_summary>The primary objective protocol estimate complete response rate three course association rituximab , navelbine , ifosfamide , mitoxantrone , prednisone relapse aggressive non hodgkin 's B-cell lymphoma</brief_summary>
	<brief_title>Efficacy , Safety Treatment R NIMP Relapsed Aggressive Lymphomas</brief_title>
	<detailed_description>Phase II study efficacy toxicity rituximab , navelbine , ifosfamide , mitoxantrone , prednisone relapse aggressive non hodgkin 's B-cell lymphoma . The study intervention administration 3 course abovementioned drug , witch dos detail . Remission assess investigator free proceed kind consolidation , decide best patient ( high dose standard chemotherapy ) . The addition Rituximab NIMP protocol warrant basis previous publication wtich show significant advantage addition chemotherapy complete remission rate overall survival . Navelbine show interesting activity lymphoma relapse . Mitoxantrone good toxicity profile patient prevously receive anthracyclines , much cross resistance two drug . Ifosfamide commonly use treatment relapsed refractory lymphoma , low hematologic toxicity profile good antitumor activity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Both gender , 18 75 year old CD 20+ large cell lymphoma In first relapse No previous autologous stem cell transplantation relapse 12 month autologous stem cell transplantation Ann Arbor stage I , II , III ou IV ECOG 0,1 2 Signed inform consent age : 18 75 year old type lymphoma Informed consent sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>relapse aggressive B-cell lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>